ArticleClinical interventions in aging2025
MicroRNA-874-3p is a Potential Contributor to Primary Hyperparathyroidism-Induced Osteoporosis.
Article in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bone aging: a paradigm of multiscale degeneration and targeted rejuvenation.Bone research · 2026Review
- FTO in Bone Diseases: Functions, Mechanisms and Therapeutic Potential.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulation of microRNAs contributes to bone diseases. However, the microRNAs involved in primary hyperparathyroidism (PHPT)-induced osteoporosis remain unknown. Methods: The parathyroid tissue samples were obtained from PHPT patients with or without osteoporosis (n = 5/group) during parathyroid resection and subjected to high throughput microRNA sequencing. The differentially expressed microRNAs were identified and further verified using qRT-PCR. Alizarin Red Staining was performed to detected the osteogenic differentiation. Gain- and loss-of-function assays were performed to investigate the role of miR-874-3p, which was upregulated in PHPT patients with osteoporosis, in human mesenchymal stem cells (hMSCs) undergoing osteoblastic differentiation. Results: We identified 32 significantly upregulated and 18 significantly downregulated microRNAs in PHPT patients with osteoporosis. miR-874-3p was increased in PHPT osteoporosis patients, meanwhile, miR-874-3p in parathyroid tissue and peripheral blood extracellular vesicles of PHPT osteoporosis mice were increased. The miR-874-3p level was remarkably elevated in hMSCs grown in osteogenic medium. Overexpression of miR-874-3p repressed the hMSC osteogenic differentiation and reduced the osteogenic marker expression in hMSCs, whereas miR-874-3p inhibitor showed a contrasting effect. The results of the dual luciferase reporting system showed that miR-874-3p could reduce the luciferase activity of wild-type FTO-WT-3 '-UTR. However, there was no significant change in the luciferase activity of the mutant compared with the control group. Conclusion: MiR-874-3p might specifically binds to FTO suppress osteogenic differentiation of hMSCs, thereby contributing to the development of osteoporosis in PHPT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.